Hematologic Disorders in Ebola-Infected Patients During the Tenth Outbreak in Butembo, Democratic Republic of Congo: Hemogram Analysis of Ebola Virus Disease Patients During the Outbreak in Butembo 2019–2020

Abstract

Background: Hematologic disorders occur frequently in patients with Ebola virus disease (EVD) and are characterized by one or several abnormalities in blood cells, including hemostasis, which is poorly documented. This study described the hematologic abnormalities of Ebola patients and the impact on the outcomes of patients who were admitted with EVD.

Methods: This was a retrospective observational study of patients recruited from 1 February 2019 to 25 June 2020 from Ebola Treatment Centers in Butembo and Katwa. Clinical and hemogram parameters at the time of admission and outcomes were collected. Descriptive statistics and logistic regression were performed with a significance level of 0.05. The analyses were carried out using Rstudio software.

Results: Among 299 patients hospitalized during the study period, only 129 were included in the analysis. The mean age was 29.9 ± 18.6 years with a female-to-male ratio of 1.2. Only 13 patients (10 %) had been vaccinated against the Ebolazaire virus. The hematologic abnormalities included anemia (55.8%), hyperleukocytosis (36.4%), leukopenia (3.1%), thrombopenia (32.6%), and thrombocytosis (30.2%). Only anemia was statistically significantly correlated with increased viral load. Anemia (OR, 4.07; 95% CI, 1.59–11.3) was shown to be an independent risk factor for mortality in patients with EVD based on multivariate analysis.

Conclusions: EVD is responsible for major hematologic abnormalities that contribute to increased patient mortality.

Keywords

blood count / hematologic / associated factors / Ebola patients / Kinshasa / D.R.C.

References

[1] Biedenkopf N, Bukreyev A, Chandran K, Di Paola N, Formenty PBH, Griffiths A, et al. Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae. Arch Virol. 2023; 168(8): 220.

[2] Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994; 199(2): 469-473.

[3] Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of Ebola virus disease. Annu Rev Pathol. 2017; 12: 387-418.

[4] Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa——clinical manifestations and management. N Engl J Med. 2014; 371(22): 2054-2057.

[5] Sospeter SB, Udohchukwu OP, Ruaichi J, Nchasi G, Paul IK, Kanyike AM, et al. Ebola outbreak in DRC and Uganda; an East African public health concern. Health Sci Rep. 2023; 6(8): e1448.

[6] Malik S, Kishore S, Nag S, Dhasmana A, Preetam S, Mitra O, et al. Ebola virus disease vaccines: development, current perspectives & challenges. Vaccines (Basel). 2023; 11(2): 268.

[7] Doshi RH, Garbern SC, Kulkarni S, Perera SM, Fleming MK, Muhayangabo RF, et al. Ebola vaccine uptake and attitudes among healthcare workers in North Kivu, Democratic Republic of the Congo, 2021. Front Public Health. 2023; 11: 1080700.

[8] Schaefer GO. If it walks like a duck…: Monitored Emergency Use of Unregistered and Experimental Interventions (MEURI) is research. J Med Ethics. 2024; 50(9): 606-611.

[9] Smither SJ, O’Brien LM, Eastaugh L, Woolley T, Lever S, Fletcher T, et al. Haemostatic changes in five patients infected with Ebola virus. Viruses. 2019; 11(7): 647.

[10] Liu DX, Pahar B, Perry DL, Xu H, Cooper TK, Huzella LM, et al. Depletion of bone marrow hematopoietic cells in Ebolavirus-infected rhesus macaques: a possible cause of hematologic abnormalities in Ebolavirus disease. Am J Pathol. 2023; 193(12): 2031-2046.

[11] Skrable K, Roshania R, Mallow M, Wolfman V, Siakor M, Levine AC. The natural history of acute Ebola virus disease among patients managed in five Ebola treatment units in West Africa: a retrospective cohort study. PLoS Negl Trop Dis. 2017; 11(7): e0005700.

[12] Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015; 15(11): 1292-1299.

[13] Galán-Huerta K, Arellanos-Soto D, Rivas-Estilla AM, Bravo-de la Cruza V, Ramos-Jiménez J. Ebola virus disease 2014. Medicina Universitaria 2014; 16(65): 207-215.

[14] Kjaldgaard L, Claude KM, Mukadi-Bamuleka D, Kitenge-Omasumbu R, Dixit D, Edidi-Atani F, et al. Virus kinetics and biochemical derangements among children with Ebolavirus disease. EClinicalMedicine. 2022; 53: 101638.

[15] Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381(24): 2293-2303.

[16] Jaspard M, Mulangu S, Juchet S, Serra B, Dicko I, Lang HJ, et al. Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo. EClinicalMedicine. 2022; 54: 101699.

[17] Beam EL, Schwedhelm MM, Boulter KC, Vasa AM, Larson L, Cieslak TJ, et al. Ebola virus disease: clinical challenges, recognition, and management. Nurs Clin North Am. 2019; 54(2): 169-180.

[18] Wing K, Oza S, Houlihan C, Glynn JR, Irvine S, Warrell CE, et al. Surviving Ebola: a historical cohort study of Ebola mortality and survival in Sierra Leone 2014-2015. PLoS One. 2018; 13(12): 1-17.

[19] Iampietro M, Younan P, Nishida A, Dutta M, Lubaki NM, Santos RI, et al. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathog. 2017; 13(5): 1-27.

[20] Handa A, Dhooria S, Sehgal IS, Agarwal R. Primary cavitary sarcoidosis: a case report, systematic review, and proposal of new diagnostic criteria. Lung India. 2018; 35(1): 41-46.